surmount-1 trial tirzepatide non-diabetic obesity weight loss once weekly for the treatment of in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 🔴Tirzepatide for obesity and diabetes

T vn, chm sc ng hng cng khch hng, c vn g lun sn sng h tr

The pharmacological profile of GHK-Cu observed in preclinical models covers a broad spectrum of activity: Stimulation of extracellular matrix synthesis influence on the production of collagen, elastin and glycosaminoglycans in dermal fibroblasts Pro-regenerative and pro-angiogenic effects in in vivo and in vitro wound healing models Modulation of gene expression in transcriptomic studies, the impact on hundreds of tissue repair and antioxidant defense genes Transport of copper ions GHK as a physiological carrier of Cu, a cofactor of matrix enzymes Antioxidant and anti-inflammatory activity reduction of oxidative stress markers in cell models GHK-Cu is a model ligand for testing in the group of plasma peptides connective tissue remodeling and copper biology combines a signaling function with trace element transport, making it a tool for studying the interface between copper metabolism and extracellular matrix repair

This evidence suggests that using these treatments together, leveraging their complementary actions, could enhance their effectiveness [101]

At the same time, the two peptides appear to have a comparable risk and side effect profile in weight loss settings